Nuclear factor-κB as a therapeutic target in critical care medicine

Critical Care Medicine

Volumn 31, Issue 1 SUPPL., 2003, Pages

  Zingarelli, Basilia ^a   Sheehan, Maeve ^a   Wong, Hector R ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Inflammation; Inhibitor B ; I B kinases; Nuclear factor B inhibitors; Sepsis

Indexed keywords

ANTIOXIDANT; CURCUMIN; DEXAMETHASONE; GLUCOCORTICOID; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NATURAL PRODUCT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROTEASOME INHIBITOR; SALAZOSULFAPYRIDINE;

ADULT RESPIRATORY DISTRESS SYNDROME; APOPTOSIS; GENE EXPRESSION; HUMAN; INFLAMMATION; INTENSIVE CARE; ISCHEMIA; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK; TISSUE INJURY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENE THERAPY; IMMUNOLOGY; METHODOLOGY; SEPSIS; SHOCK;

CRITICAL CARE; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; INFLAMMATION; NF-KAPPA B; SEPSIS; SHOCK;

EID: 0037247748     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200301001-00015     Document Type: Review

References (89)

1. Senftleben U, Karin M: The IKK/NF-κB pathway. Crit Care Med 2002; 30:S18-S26
2. Karin M, Lin A: NF-κB at the crossroads of life and death. Nat Immun 2002; 3:221-227
3. Ghosh S, Karin M: Missing pieces in the NF-κB puzzle. Cell 2002; 109:S81-S96
4. Ito CY, Kazantsev AG, Baldwin AS: Three NF-κB sites in the IκB-α promoter are required for induction of gene expression by TNFα. Nucleic Acids Res 1994; 22:3787-3792
5. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, et al: Inducible nuclear expression of newly synthesized IκBα negatively regulates DNA-binding and transcriptional activities of NF-κB. Mol Cell Biol 1995; 15:2689-2696
6. Chen Lf, Fischle W, Verdin E, et al: Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001; 293:1653-1657
7. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 2000; 18:621-663
8. DiDonato JA, Hayakawa M, Rothwarf DM, et al: A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 1997; 388:548-554
9. Mercurio F, Zhu H, Murray BW, et al: IKK-1 and IKK-2: Cytokine-activated IκB kinases essential for NF-κB activation. Science 1997; 278:860-866
10. Mann MJ, Dzau VJ: Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 2000; 106:1071-1075
11. Bielinska A, Shivdasani RA, Zhang LQ, et al: Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990; 250:997-1000
12. Morishita R, Gibbons GH, Horiuchi M, et al: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995; 92:5855-5859
13. Mann MJ, Whittemore AD, Donaldson MC, et al: Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354:1493-1498
14. Kupatt C, Wichels R, Deiss M, et al: Retroinfusion of NF-κB decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and retroinfusion in pigs. Gene Ther 2002; 9:518-526
15. Yokoseki O, Suzuki J, Kitabayashi H, et al: cis Element decoy against nuclear factor-κB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 2001; 89:899-906
16. Tomita N, Morishita R, Tomita S, et al: Transcription factor decoy for NF-κB inhibits TNF-α-induced cytokine and adhesion molecule expression in vivo. Gene Ther 2000; 7:1326-1332
17. Feeley BT, Miniati DN, Park AK, et al: Nuclear factor-κB transcription factor decoy treatment inhibits graft coronary artery, disease after cardiac transplantation in rodents. Transplantation 2000; 70:1560-1568
18. D'Acquisto F, Ialenti A, Ianaro A, et al: Local administration of transcription factor decoy oligonucleotides to nuclear factor-κB prevents carrageenin-induced inflammation in rat hind paw. Gene Ther 2000; 7:1731-1737
19. Tomita N, Morishita R, Lan HY, et al: In vivo administration of a nuclear transcription factor-κB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 2000; 11:1244-1252
20. Tomita T, Takeuchi E, Tomita N, et al: Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999; 42:2532-2542
21. Denk A, Goebeler M, Schmid S, et al: Activation of NF-κB via the IκB kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J Biol Chem 2001; 276:28451-28458
22. Hirotani S, Otsu K, Nishida K, et al: Involvement of nuclear factor-κB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002; 105:509-515
23. Brouard S, Berberat PO, Tobiasch E, et al: Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-κB to protect endothelial cells from tumor necrosis factor-α-mediated apoptosis. J Biol Chem 2002; 277:17950-17961
24. Bohrer H, Qiu F, Zimmermann T, et al: Role of NFκB in the mortality of sepsis. J Clin Invest 1997; 100:972-985
25. Adams J, Palombella VJ, Elliott PJ: Proteasome inhibition: A new strategy in cancer treatment. Invest New Drugs 2000; 18:109-121
26. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, et al: Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 1995; 217:1070-1077
27. Gregory MA, Hann SR: c-Myc proteolysis by the ubiquitin-proteasome pathway: Stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000; 20:2423-2435
28. Stinchcombe TE, Mitchell BS, Depeik-Smith N, et al: PS-341 is active in mulptiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with multiple myeloma. Blood 2000; 96(Suppl 1):516a
29. Barnes PJ, Adcock I: Anti-inflammatory actions of steroids: Molecular mechanisms. Trends Pharmacol Sci 1993; 14:436-441
30. Almawi WY, Melemedjian OK: Negative regulation of nuclear factor-κB activation and function by glucocorticoids. J Mol Endocrinol 2002; 28:69-78
31. Auphan N, DiDonato JA, Rosette C, et al: Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270:286-290
32. Scheinman RI, Cogswell PC, Lofquist AK, et al: Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283-286
33. Heck S, Bender K, Kullmann M, et al: IκBα-independent downregulation of NF-κB activity by glucocorticoid receptor. EMBO J 1997 16:4698-4707
34. De Bosscher K, Schmitz ML, Vanden Berghe W, et al: Glucocorticoid-mediated repression of nuclear factor-κB-dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci U S A 1997; 94:13504-13509
35. Adcock IM, Brown CR, Gelder CM, et al: Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am J Physiol 1995; 268:C331-C338
36. Scheinman RI, Gualberto A, Jewell CM, et al: Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol 1995; 15:943-953
37. Nissen RM, Yamamoto KR: The glucocorticoid receptor inhibits NF-κB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000; 14:2314-2329
38. Reichardt HM, Tuckermann JP, Gottlicher M, et al: Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 2001; 20:7168-7173
39. Sheppard KA, Phelps KM, Williams AJ, et al: Nuclear integration of glucocorticoid receptor and nuclear factor-κB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem 1998; 273:29291-29294
40. De Bosscher K, Vanden Berghe W, Vermeulen L, et al: Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci U S A 2000; 97:3919-3924
41. Meduri GU, Tolley EA, Chrousos GP, et al: Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: Evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002; 165:983-991
42. Thiele K, Bierhaus A, Autschbach F, et al: Cell specific effects of glucocorticoid treatment on the NF-κBp65/IκBα system in patients with Crohn's disease. Gut 1999; 45:693-704
43. Vane JR, Botting RM: Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104:2S-8S
44. Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15:2057-2072
45. Kopp E, Ghosh S: Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994; 265:956-959
46. Pierce JW, Read MA, Ding H, et al: Salicylates inhibit IκB-α phosphorylation, endothelialleukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 1996; 156:3961-3969
47. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998; 396:77-80
48. Wahl C, Liptay S, Adler G, et al: Sulfasalazine: A potent and specific inhibitor of nuclear factor κB. J Clin Invest 1998; 101:1163-1174
49. Egan LJ, Mays DC, Huntoon CJ, et al: Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999; 274:26448-26453
50. Palayoor ST, Youmell MY, Calderwood SK, et al: Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18:7389-7394
51. Tegeder I, Niederberger E, Israr E, et al: Inhibition of NF-κB and AP-1 activation by R- and S-flurbiprofen. FASEB J 2001; 15:595-597
52. Yamamoto Y, Yin MJ, Lin KM, et al: Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 1999; 274:27307-27314
53. Fiebich BL, Hofer TJ, Lieb K, et al: The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 and α1-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IκBα. Neuropharmacology 1999; 38:1325-1333
54. Matasic R, Dietz AB, Vuk-Pavlovic S: Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology 2000; 101:53-60
55. Niederberger E, Tegeder I, Vetter G, et al: Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-κB. FASEB J 2001; 15:1622-1624
56. Hall IH, Starnes CO Jr, Lee KH, et al: Mode of action of sesquiterpene lactones as anti-inflammatory agents. J Pharm Sci 1980; 69:537-543
57. Heinrich M, Robles M, West JE, et al: Ethnopharmacology of Mexican asteraceae (Compositae). Annu Rev Pharmacol Toxicol 1998; 38:539-565
58. Schinella GR, Giner RM, Recio MC, et al: Anti-inflammatory effects of South American Tanacetum vulgate. J Pharm Pharmacol 1998; 50:1069-1074
59. Giordano OS, Pestchanker MJ, Guerreiro E, et al: Structure-activity relationship in the gastric cytoprotective effect of several sesquiterpene lactones. J Med Chem 1992; 35:2452-2458
60. Wendel GH, Maria AO, Mohamed F, et al: Effect of dehydroleucodine in experimental colitis in rats and mice. Pharmacol Res 1999; 40:339-344
61. Bork PM, Schmitz ML, Kuhnt M, et al: Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-κB. FEBS Lett 1997; 402:85-90
62. Hehner SP, Hofmann TG, Droge W, et al: The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-κB by targeting the IκB kinase complex. J Immunol 1999; 163:5617-5623
63. Hehner SP, Heinrich M, Bork PM, et al: Sesquiterpene lactones specifically inhibit activation of NF-κB by preventing the degradation of IκB-α and IκB-β. J Biol Chem 1998; 273:1288-1297
64. Wong HR, Menendez IY: Sesquiterpene lactones inhibit inducible nitric oxide synthase gene expression in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun 1999; 262:375-380
65. Mazor RL, Menendez IY, Ryan MA, et al: Sesquiterpene lactones are potent inhibitors of interleukin 8 gene expression in cultured human respiratory epithelium. Cytokine 2000; 12:239-245
66. Picman AK, Rodriguez E, Towers GH: Formation of adducts of parthenin and related sesquiterpene lactones with cysteine and glutathione. Chem Biol Interact 1979; 28:83-89
67. Lyp, Knorre A, Schmidt TJ, et al: The antiinflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-κB by directly targeting p65. J Biol Chem 1998; 273:33508-33516
68. Zingarelli B, Hake PW, Denenberg A, et al: Sesquiterpene lactone parthenolide, an inhibitor of IκB kinase complex and nuclear factor-κB, exerts beneficial effects in myocardial reperfusion injury. Shock 2002; 17:127-134
69. Sheehan M, Wong HR, Hake PW, et al: Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol 2002; 61:953-963
70. Sheehan M, Wong HR, Hake PW, et al: Protective effects of isohelenin, an inhibitor of nuclear factor-κB, in endotoxic shock in rats. J Endotoxin Res 2002; 8:99-107
71. Yang CS, Maliakal P, Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002; 42:25-54
72. Ahmad N, Gupta S, Mukhtar H: Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κB in cancer cells versus normal cells. Arch Biochem Biophys 2000; 376:338-346
73. Yang F, Oz HS, Barve S, et al: The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting IκB kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 2001; 60:528-533
74. Yang F, de Villiers WJ, McClain CJ, et al: Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. J Nutr 1998; 128:2334-2340
75. Kumar A, Dhawan S, Hardegen NJ, et al: Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-κB activation. Biochem Pharmacol 1998; 55:775-783
76. Dunsmore KE, Chen PG, Wong HR: Curcumin, a medicinal herbal compound capable of inducing the heat shock response. Crit Care Med 2001; 29:2199-2204
77. Umezawa K, Ariga A, Matsumoto N: Naturally occurring and synthetic inhibitors of NF-κB functions. Anticancer Drug Des 2000; 15:239-244
78. Takeshita S, Gage JR, Kishimoto T, et al: Differential regulation of IL-6 gene transcription and expression by IL-4 and IL-10 in human monocytic cell lines. J Immunol 1996; 156:2591-2598
79. Romano MF, Lamberti A, Petrella A, et al: IL-10 inhibits nuclear factor-kappa B/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes. J Immunol 1996; 156:2119-2123
80. Lentsch AB, Shanley TP, Sarma V, et al: In vivo suppression of NF-κB and preservation of IκBa by interleukin-10 and interleukin-13. J Clin Invest 1997; 100:2443-2448
81. Moore KW, de Waal Malefyt R, Coffman RL, et al: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765
82. Schottelius AJ, Mayo MW, Sartor RB, et al: Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding. J Biol Chem 1999; 274:31868-31874
83. Mihm S, Ennen J, Pessara U, et al: Inhibition of HIV-1 replication and NF-κB activity by cysteine and cysteine derivatives. AIDS 1991; 5:497-503
84. Schreck R, Albermann K, Baeuerle PA: Nuclear factor κB: an oxidative stress-responsive transcription factor of eukaryotic cells. Free Radic Res Commun 1992; 17:221-237
85. Schreck R, Meier B, Mannel DN, et al: Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J Exp Med 1992; 175:1181-1194
86. Suzuki YJ, Packer L: Inhibition of NF-κB activation by vitamin E derivatives. Biochem Biophys Res Commun 1993; 193:277-283
87. Sen CK, Packer L: Antioxidant and redox regulation of gene transcription. FASEB J 1996; 10:709-720
88. Suzuki YJ, Packer L: Inhibition of NF-κB DNA binding activity by α-tocopheryl succinate. Biochem Mol Biol Int 1993; 31:693-700
89. Bonizzi G, Piette J, Schoonbroodt S, et al: Reactive oxygen intermediate-dependent NF-κB activation by interleukin-1β requires 5-lipoxygenase or NADPH oxidase activity. Mol Cell Biol 1999; 19:1950-1960